Overview
Prevotella histicola is an anaerobic, Gram-negative bacterium belonging to the genus Prevotella within the phylum Bacteroidota. It is a commensal organism found in both the gut and oral cavity, where it typically resides without causing harm. Research suggests that P. histicola may possess remarkable systemic immunomodulatory properties, capable of producing anti-inflammatory effects throughout the body when administered orally. This has led to its development as a pharmaceutical-grade next-generation probiotic preparation (EDP1815) by Evelo Biosciences, which has cleared IND status for clinical trials targeting inflammatory and autoimmune diseases.
Classification
P. histicola belongs to the family Prevotellaceae within the order Bacteroidales. It is related to other Prevotella species found in the human microbiome, including Prevotella copri and Prevotella melaninogenica, though it occupies distinct ecological niches in the duodenum and oral cavity. Unlike some Prevotella species that have mixed health associations, P. histicola has primarily been studied for its beneficial immune-modulating effects.
Key Characteristics
P. histicola is notable for its ability to produce systemic anti-inflammatory effects when administered enterally, meaning its immune-modulating influence is not limited to the gut. In preclinical models, it has been shown to suppress pro-inflammatory cytokines including IL-17 and IFN-gamma while promoting regulatory immune pathways. The EDP1815 pharmaceutical preparation uses a non-colonizing formulation of a single P. histicola strain, which may simplify dosing and safety considerations. Additionally, oral administration of P. histicola has been associated with improved sleep parameters in rodent models, including increased total sleep time (p<0.001) and REM sleep (p<0.05), suggesting gut-brain axis signaling via vagal pathways.
Health Significance
The therapeutic potential of P. histicola appears to span multiple inflammatory and autoimmune conditions. Preclinical studies have demonstrated suppression of experimental arthritis in HLA-DQ8 humanized mice, and EDP1815 has shown immunomodulatory effects in murine models of celiac disease and type 1 diabetes. The EDP1815 clinical pipeline includes investigations for psoriasis and atopic dermatitis. However, it is important to note that P. histicola effects may be context-dependent, as the broader Prevotella genus includes species with variable health associations. Results from animal studies may not fully translate to human outcomes, and ongoing clinical trials will be critical for establishing safety and efficacy in human populations.